New tentative approval for MSN drug dabigatran etexilate mesylate
  1. Biotechnology

New tentative approval for MSN drug dabigatran etexilate mesylate

Written by Posted on Less than 0 min read

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound.

Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE.

Nine suppliers are listed for this compound. There are ten tentative approvals for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at

Member since

More from DrugPatentWatch – Make Better Decisions

New patent for Santen drug OMLONTI – DrugPatentWatch
  1. Biotechnology

New patent for Santen drug OMLONTI – DrugPatentWatch

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for OMLONTI Omlonti is a drug marketed by Santen and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. This drug has one hundred and fourteen patent family members in thirty-two countries. The generic ingredient […]
Written by
New tentative approval for Alembic drug dabigatran etexilate mesylate
  1. Biotechnology

Which pharmaceutical companies have the most SPCs in Ireland?

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European Union and select others to encourage pharmaceutical innovation bycompensating for the long time needed to obtain regulatory approval for drugs. SPCscome into force only after the corresponding general […]
Written by
New tentative approval for MSN drug dabigatran etexilate mesylate
  1. Biotechnology

New patent for Abbvie drug RINVOQ LQ

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for RINVOQ+LQ Rinvoq Lq is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib […]
Written by
New tentative approval for Sandoz Inc drug rifaximin
  1. Biotechnology

New tentative approval for Sandoz Inc drug rifaximin

Copyright © DrugPatentWatch. Initially printed at https://www.drugpatentwatch.com/weblog/ Rifaximin is the generic ingredient in a single branded drug marketed by Salix Pharms and is included in a single NDA. There are twenty-nine patents defending this compound. Drug patent litigation for RIFAXIMIN. This ingredient has 100 and eigthy-two patent members of the family in thirty-nine nations. Three […]
Written by
New tentative approval for Alembic drug dabigatran etexilate mesylate
  1. Biotechnology

New tentative approval for Alembic drug dabigatran etexilate mesylate

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […]
Written by
New tentative approval for Alembic drug dabigatran etexilate mesylate
  1. Biotechnology

New tentative approval for Alembic drug dabigatran etexilate mesylate

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […]
Written by
  1. Biotechnology

Drug Patent Expirations for the Week of October 22, 2023 – DrugPatentWatch

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ FINACEA (azelaic acid) Leo pharma as Patent: 8,900,554 Expiration: Oct 24, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com Make Better Decisions with DrugPatentWatch » Start Your Free Trial Today « Copyright © […]
Written by
New tentative approval for Alembic drug dabigatran etexilate mesylate
  1. Biotechnology

New patent expiration for United Therap drug ORENITRAM

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for ORENITRAM Orenitram is a drug marketed by United Therap and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for ORENITRAM. This drug has fifty-nine patent […]
Written by
  1. Biotechnology

New patent expiration for Novartis drug VOTRIENT – DrugPatentWatch

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for VOTRIENT Votrient is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. This drug has thirty-four patent family members in twenty-five countries. The generic ingredient in VOTRIENT is […]
Written by
  1. Biotechnology

New patent expiration for Ferrer Internacional drug XEPI – DrugPatentWatch

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for XEPI Xepi is a drug marketed by Ferrer Internacional and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. This drug has forty-four patent family members in twenty-five countries. The generic ingredient in XEPI […]
Written by
  1. Biotechnology

New patent for Beigene drug BRUKINSA – DrugPatentWatch

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. This drug has forty-nine patent family members in twenty-eight countries. The generic ingredient in BRUKINSA is […]
Written by
New tentative approval for Alembic drug dabigatran etexilate mesylate
  1. Biotechnology

Which pharmaceutical drugs have the most drug patents in United Kingdom?

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the drugs with the most patents in United Kingdom. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. The companies with the greatest patent coverage in United Kingdom are: Onzetra Xsail Xhance Evzio Evzio (autoinjector) […]
Written by
New tentative approval for Sandoz Inc drug rifaximin
  1. Biotechnology

New patent for Neurocrine drug ONGENTYS

Copyright © DrugPatentWatch. Initially revealed at https://www.drugpatentwatch.com/weblog/ Annual Drug Patent Expirations for ONGENTYS Ongentys is a drug marketed by Neurocrine and is included in a single NDA. It’s out there from two suppliers. There are 9 patents defending this drug. ONGENTYS drug worth tendencies. This drug has 100 and 13 patent relations in thirty-one international […]
Written by
New tentative approval for Alembic drug dabigatran etexilate mesylate
  1. Biotechnology

New patent for Vanda Pharms drug HETLIOZ

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for HETLIOZ. This drug has one […]
Written by
New tentative approval for Sandoz Inc drug rifaximin
  1. Biotechnology

New patent expiration for Merck Sharp drug DUTREBIS

Copyright © DrugPatentWatch. Initially revealed at https://www.drugpatentwatch.com/weblog/ Annual Drug Patent Expirations for DUTREBIS Dutrebis is a drug marketed by Merck Sharp Dohme and is included in a single NDA. There are two patents defending this drug. The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. Extra particulars can be found on the lamivudine; raltegravir potassium […]
Written by
New tentative approval for Alembic drug dabigatran etexilate mesylate
  1. Biotechnology

Which pharmaceutical drugs have the most drug patents in Austria?

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the drugs with the most patents in Austria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. The companies with the greatest patent coverage in Austria are: Adasuve Abilify Maintena Kit Vistogard Zetia Abilify Nucynta […]
Written by
Next
No Comments
Leave a comment Cancel
Comments to: New tentative approval for MSN drug dabigatran etexilate mesylate

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.